The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...
WASHINGTON (Reuters) - The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with over 50% of ...
Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
Surmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...